全文获取类型
收费全文 | 32078篇 |
免费 | 2312篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 257篇 |
儿科学 | 1140篇 |
妇产科学 | 766篇 |
基础医学 | 4078篇 |
口腔科学 | 694篇 |
临床医学 | 3591篇 |
内科学 | 7790篇 |
皮肤病学 | 771篇 |
神经病学 | 3179篇 |
特种医学 | 835篇 |
外国民族医学 | 8篇 |
外科学 | 3222篇 |
综合类 | 327篇 |
一般理论 | 8篇 |
预防医学 | 2947篇 |
眼科学 | 591篇 |
药学 | 2110篇 |
中国医学 | 72篇 |
肿瘤学 | 2121篇 |
出版年
2023年 | 191篇 |
2022年 | 341篇 |
2021年 | 727篇 |
2020年 | 433篇 |
2019年 | 724篇 |
2018年 | 864篇 |
2017年 | 581篇 |
2016年 | 650篇 |
2015年 | 752篇 |
2014年 | 1050篇 |
2013年 | 1387篇 |
2012年 | 2170篇 |
2011年 | 2209篇 |
2010年 | 1134篇 |
2009年 | 1071篇 |
2008年 | 1803篇 |
2007年 | 1847篇 |
2006年 | 1812篇 |
2005年 | 1776篇 |
2004年 | 1634篇 |
2003年 | 1538篇 |
2002年 | 1408篇 |
2001年 | 539篇 |
2000年 | 469篇 |
1999年 | 530篇 |
1998年 | 282篇 |
1997年 | 256篇 |
1996年 | 255篇 |
1995年 | 199篇 |
1994年 | 196篇 |
1993年 | 185篇 |
1992年 | 394篇 |
1991年 | 350篇 |
1990年 | 350篇 |
1989年 | 344篇 |
1988年 | 266篇 |
1987年 | 282篇 |
1986年 | 284篇 |
1985年 | 297篇 |
1984年 | 223篇 |
1983年 | 184篇 |
1982年 | 128篇 |
1979年 | 231篇 |
1978年 | 164篇 |
1977年 | 150篇 |
1976年 | 125篇 |
1975年 | 154篇 |
1974年 | 177篇 |
1973年 | 153篇 |
1972年 | 158篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
Troppmair Teresa Egger J. Krösbacher A. Zanvettor A. Schinnerl A. Neumayr A. Baubin M. 《Der Anaesthesist》2022,71(4):272-280
Die Anaesthesiologie - Die Qualität eines Rettungssystems zeichnet sich auch durch den effizienten Einsatz seiner personellen und Fahrzeugressourcen aus. So können im berechtigten Fall... 相似文献
2.
3.
4.
Maria Gonzalez-Cao Cristina Carrera Juan Francisco Rodriguez Moreno Pedro Rodríguez-Jiménez Mónica Antoñanzas Basa Rosa Feltes Ochoa Teresa Puertolas Eva Muñoz-Couselo José Luis Manzano Ivan Marquez-Rodas Juan Martín-Liberal Ainara Soria Pilar Lopez Criado Almudena Garcia-Castaño Aram Boada Pablo Ayala de Miguel Susana Puig Guillermo Crespo Alfonso Berrocal 《Journal of the American Academy of Dermatology》2021,84(5):1412-1415
5.
6.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献7.
8.
9.
Samira Marín-Romero Teresa Elías-Hernández María Isabel Asensio-Cruz Rocío Ortega-Rivera Raquel Morillo-Guerrero Javier Toral Emilio Montero Verónica Sánchez Elena Arellano José María Sánchez-Díaz Macarena Real-Domínguez Remedios Otero-Candelera Luis Jara-Palomares 《Archivos de bronconeumología》2019,55(12):619-626
IntroductionScales for predicting venous thromboembolism (VTE) recurrence are useful for deciding the duration of the anticoagulant treatment. Although there are several scales, the most appropriate for our setting has not been identified. For this reason, we aimed to validate the DASH prediction score and the Vienna nomogram at 12 months.MethodsThis was a retrospective study of unselected consecutive VTE patients seen between 2006 and 2014. We compared the ability of the DASH score and the Vienna nomogram to predict recurrences of VTE. The validation was performed by stratifying patients as low-risk or high-risk, according to each scale (discrimination) and comparing the observed recurrence with the expected rate (calibration).ResultsOf 353 patients evaluated, 195 were analyzed, with an average age of 53.5 ± 19 years. There were 21 recurrences in 1 year (10.8%, 95% CI: 6.8%-16%). According to the DASH score, 42% were classified as low risk, and the rate of VTE recurrence in this group was 4.9% (95% CI: 1.3%-12%) vs. the high-risk group that was 15% (95% CI: 9%-23%) (p <.05). According to the Vienna nomogram, 30% were classified as low risk, and the rate of VTE recurrence in the low risk group vs. the high risk group was 4.2% (95% CI:0.5%-14%) vs. 16.2% (95% CI: 9.9%-24.4%) (p <.05).ConclusionsOur study validates the DASH score and the Vienna nomogram in our population. The DASH prediction score may be the most advisable, both because of its simplicity and its ability to identify more low-risk patients than the Vienna nomogram (42% vs. 30%). 相似文献
10.